| DB ID | MyCo_1814 |
| Title | Antifungal type 1 responses are upregulated in IL-10-deficient mice |
| Year | 1999 |
| PMID | 10580272 |
| Fungal Diseases involved | Invasive candidiasis |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | albicans |
| Organism | Candida albicans |
| Ethical Statement | Procedures involving animals and their care were conducted in conformity with national and international laws and policies. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Animal |
| Host Common name | Mice |
| Host Scientific name | Mus musculus |
| Biomarker Name | IL-12 |
| Biomarker Full Name | Interleukin-12 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Italy |
| Cohort | Breeding pairs of homozygous IL-10-deficient (IL-10–/–) and control (IL-10+/+) C57BL/6 mice were bred under specific pathogen-free conditions. These mice have been backcrossed for > 10 generations on the C57BL/6 background. Mice of both sexes, 8 to 10 weeks old, were used. Procedures involving animals and their care were conducted in conformity with national and international laws and policies. |
| Cohort No. | None |
| Age Group | None |
| P Value | p<0.05 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | The opportunistic fungi Candida albicans and Aspergillus fumigatus cause a variety of fungal diseases, particularly in immunocompromised patients. Invasive candidiasis and aspergillosis have been reported with increasing frequency in patients with chemotherapy-induced neutropenia. However, chronic forms of these infections that are independent of neutropenia have also been noticed. Both agents cause infections in patients with AIDS, although at different stages of the disease. Despite advances in therapy, candidiasis and aspergillosis can be difficult to successfully treat, especially in the severely immunocompromised hosts. Understanding regulation of the host immune response as an adjunct to antimicrobial therapy may offer new strategies for prevention and treatment of these infections. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA Kit (PharMingen) |
| Assay Data | None |
| Validation Techniques used | ELISA, RT-PCR |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
